Olukunle Ajagbe, MD
Pulmonary Disease · McComb, MSNPI 1982632063
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,683 of the $25,901 with a category attached, or 60.5%. 41 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 38.6% of the total. Reporting peaked in 2020 at $11,339 and has fallen 71.1% since, to $3,280 in 2025. Among pulmonary disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 857 payments — averaging $30.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$10K
- AstraZeneca$4K
- GSK$3K
- Boehringer Ingelheim$2K
- Mylan Specialty L.p.$1K
- Sanofi$926
- plus $5K from 35 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$9,40036%
- Food & beverage$15,68361%
- Education$5182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,901 in reported general payments places this provider in the 90th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 24 | $288,369 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 255 | $190,363 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 168 | $122,217 |
| Spiriva RespimatTiotropium Bromide | 156 | $87,676 |
| Dupixent SyringeDupilumab | 23 | $85,724 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 87 | $50,168 |
| NucalaMepolizumab | 12 | $44,266 |
| SymbicortBudesonide/Formoterol Fumarate | 132 | $44,262 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $24,080 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $22,529 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $13,744 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 339 | $13,185 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $12,711 |
| Spiriva HandihalerTiotropium Bromide | 18 | $11,734 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 19 | $10,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,502 | $426,212267 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $3,101 | $294,981409 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $3,886 | $177,061319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in McComb
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
- Michal SenitkoJackson$185K
- Cameron HuxfordStarkville$155K
- L AldredHattiesburg$76K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- Jaime UngoTupelo$29K
- George AbrahamJackson$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.